Iterum Other Liab vs Non Currrent Assets Other Analysis
ITRM Stock | USD 1.80 0.18 9.09% |
Iterum Therapeutics financial indicator trend analysis is infinitely more than just investigating Iterum Therapeutics PLC recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Iterum Therapeutics PLC is a good investment. Please check the relationship between Iterum Therapeutics Other Liab and its Non Currrent Assets Other accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iterum Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
Other Liab vs Non Currrent Assets Other
Other Liab vs Non Currrent Assets Other Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Iterum Therapeutics PLC Other Liab account and Non Currrent Assets Other. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Iterum Therapeutics' Other Liab and Non Currrent Assets Other is -0.06. Overlapping area represents the amount of variation of Other Liab that can explain the historical movement of Non Currrent Assets Other in the same time period over historical financial statements of Iterum Therapeutics PLC, assuming nothing else is changed. The correlation between historical values of Iterum Therapeutics' Other Liab and Non Currrent Assets Other is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Liab of Iterum Therapeutics PLC are associated (or correlated) with its Non Currrent Assets Other. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Currrent Assets Other has no effect on the direction of Other Liab i.e., Iterum Therapeutics' Other Liab and Non Currrent Assets Other go up and down completely randomly.
Correlation Coefficient | -0.06 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Other Liab
Non Currrent Assets Other
Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.Most indicators from Iterum Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Iterum Therapeutics PLC current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iterum Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. At this time, Iterum Therapeutics' Selling General Administrative is very stable compared to the past year. As of the 14th of December 2024, Sales General And Administrative To Revenue is likely to grow to 288.20, while Tax Provision is likely to drop about 521.7 K.
2021 | 2022 | 2023 | 2024 (projected) | Reconciled Depreciation | 2.1M | 1.8M | 1.7M | 969.1K | Income Tax Expense | 705K | 301K | 613K | 527.3K |
Iterum Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Iterum Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Iterum Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 25.8M | 32.8M | 91.5M | 66.8M | 26.3M | 24.9M | |
Other Current Liab | 3.0M | 34.3M | 10.2M | 6.3M | 8.5M | 10.5M | |
Total Current Liabilities | 37.0M | 28.9M | 6.1M | 196K | 13.5M | 15.0M | |
Total Stockholder Equity | (26.2M) | (50.6M) | 50.2M | 28.0M | (6.4M) | (6.1M) | |
Net Tangible Assets | (26.2M) | (50.6M) | 46.8M | 26.3M | 23.7M | 14.9M | |
Net Debt | 2.8M | 21.3M | (2.5M) | 7.4M | 12.9M | 13.5M | |
Retained Earnings | (234.9M) | (286.9M) | (378.5M) | (422.9M) | (461.3M) | (438.2M) | |
Accounts Payable | 15.5M | 816K | 878K | 2.8M | 5.0M | 3.4M | |
Cash | 4.8M | 14.5M | 27.4M | 21.1M | 6.1M | 5.8M | |
Non Current Assets Total | 21.0M | 18.3M | 10.2M | 6.0M | 663K | 629.9K | |
Non Currrent Assets Other | 20.3M | 17.6M | 6.6M | 4.2M | 63K | 59.9K | |
Other Assets | 6.3M | 10.9M | 4.7M | 831K | 955.7K | 907.9K | |
Cash And Short Term Investments | 4.8M | 14.5M | 81.3M | 60.8M | 23.9M | 45.9M | |
Net Receivables | 1.1M | 865K | 1.2M | 513K | 233K | 221.4K | |
Common Stock Shares Outstanding | 14.5M | 24.0M | 163.4M | 12.2M | 13.0M | 12.3M | |
Short Term Investments | 1.1K | 2.4M | 53.9M | 39.7M | 17.9M | 25.4M | |
Liabilities And Stockholders Equity | 25.8M | 32.8M | 91.5M | 66.8M | 26.3M | 24.9M | |
Non Current Liabilities Total | 52.0M | 54.5M | 35.2M | 38.6M | 19.1M | 31.1M | |
Capital Surpluse | 94.2M | 203.3M | 208.5M | 235.9M | 271.3M | 173.8M | |
Other Current Assets | 6.9M | 6.0M | 717K | 1.1M | 1.4M | 2.9M | |
Other Stockholder Equity | 208.5M | 235.9M | 426.9M | 451.2M | 454.8M | 291.9M | |
Total Liab | 52.0M | 83.4M | 41.3M | 38.8M | 32.7M | 39.3M | |
Total Current Assets | 4.8M | 14.5M | 81.3M | 60.8M | 25.6M | 47.0M | |
Common Stock | 149K | 494K | 1.8M | 126K | 135K | 128.3K | |
Property Plant And Equipment Net | 572K | 421K | 91K | 69K | 600K | 365.7K | |
Net Invested Capital | (12.8M) | (8.2M) | 24.9M | 56.5M | 12.6M | 22.6M | |
Property Plant And Equipment Gross | 7.7M | 421K | 377K | 353K | 366K | 347.7K | |
Non Current Liabilities Other | 7.4M | 19.2M | 10.3M | 1.3M | 188K | 178.6K | |
Net Working Capital | (25.3M) | (20.2M) | 75.3M | 53.4M | 12.1M | 11.5M | |
Property Plant Equipment | 7.7M | 421K | 91K | 1.8M | 1.7M | 1.5M | |
Short Long Term Debt Total | 13.4M | 35.9M | 24.9M | 28.5M | 19.0M | 24.9M | |
Current Deferred Revenue | 12.7M | (7.3M) | (2.5M) | (332K) | (298.8K) | (283.9K) | |
Long Term Debt | 7.6M | 22.5M | 24.9M | 28.5M | 19.0M | 21.2M | |
Inventory | (8.0M) | (3.7M) | (3.1M) | (1.9M) | (2.1M) | (2.2M) | |
Capital Stock | 149K | 494K | 1.8M | 126K | 135K | 128.3K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iterum Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iterum Therapeutics. If investors know Iterum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iterum Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.76) | Quarterly Revenue Growth (1.00) | Return On Assets (0.73) | Return On Equity (5.56) |
The market value of Iterum Therapeutics PLC is measured differently than its book value, which is the value of Iterum that is recorded on the company's balance sheet. Investors also form their own opinion of Iterum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Iterum Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iterum Therapeutics' market value can be influenced by many factors that don't directly affect Iterum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iterum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Iterum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iterum Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.